FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613339929> ?p ?o ?g. }

• W2613339929 endingPage "487" @default.
• W2613339929 startingPage "479" @default.
• W2613339929 abstract "The phase III COMFORT (Controlled Myelofibrosis Study With Oral JAK inhibitor Treatment)-I and COMFORT-II trials in patients with intermediate-2 or high-risk myelofibrosis (MF) showed that ruxolitinib was superior to placebo and best available therapy, respectively, for improvements in spleen volume, MF-related symptoms, and overall survival (OS). However, patients managed in community settings might not have access to the methods used in the COMFORT trials. In this exploratory analysis we summarize efficacy findings of COMFORT-I using practical, community-oriented measures of patient outcomes.In this post hoc analysis of data from COMFORT-I we evaluated changes from baseline to week 12 in spleen size (palpable length and volume), patient-reported outcomes (Patient Global Impression of Change; Myelofibrosis Symptom Assessment Form; Patient-Reported Outcomes Measurement System Fatigue Scale), body weight, and serum albumin levels in 5 subgroups of ruxolitinib-treated patients on the basis of week 12 spleen length changes from baseline: (1-4) ≥ 50%, 25% to < 50%, 10% to < 25%, or < 10% reduction; and (5) worsening. OS was evaluated in ruxolitinib-treated patients with week 12 spleen length reductions from baseline ≥ 50%, 25% to < 50%, or < 25% (including worsening).In all spleen length subgroups, including patients with worsening spleen length at week 12, ruxolitinib (n = 150) was associated with improvements in spleen volume, patient-reported symptom burden, body weight, and serum albumin levels. Greater reductions in spleen length were associated with prolonged OS.A variety of assessment methods beyond palpable spleen length that are easily accessible in the community setting might be useful in evaluating the clinical benefit of ruxolitinib over time in patients with MF." @default.
• W2613339929 created "2017-05-19" @default.
• W2613339929 creator A5039057642 @default.
• W2613339929 creator A5047427155 @default.
• W2613339929 creator A5055163444 @default.
• W2613339929 creator A5067595638 @default.
• W2613339929 creator A5085521139 @default.
• W2613339929 creator A5089940133 @default.
• W2613339929 date "2017-08-01" @default.
• W2613339929 modified "2023-10-16" @default.
• W2613339929 title "Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I" @default.
• W2613339929 cites W1583257954 @default.
• W2613339929 cites W1985177017 @default.
• W2613339929 cites W2010298229 @default.
• W2613339929 cites W2016111806 @default.
• W2613339929 cites W2018254868 @default.
• W2613339929 cites W2039007892 @default.
• W2613339929 cites W2093158866 @default.
• W2613339929 cites W2111141291 @default.
• W2613339929 cites W2115351357 @default.
• W2613339929 cites W2121743767 @default.
• W2613339929 cites W2127559749 @default.
• W2613339929 cites W2142506642 @default.
• W2613339929 cites W2149055075 @default.
• W2613339929 cites W2157066112 @default.
• W2613339929 cites W2161021913 @default.
• W2613339929 cites W2162420979 @default.
• W2613339929 cites W2287857102 @default.
• W2613339929 cites W2405712018 @default.
• W2613339929 cites W2510139173 @default.
• W2613339929 cites W2529479111 @default.
• W2613339929 cites W3194956376 @default.
• W2613339929 doi "https://doi.org/10.1016/j.clml.2017.05.015" @default.
• W2613339929 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8148882" @default.
• W2613339929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28606598" @default.
• W2613339929 hasPublicationYear "2017" @default.
• W2613339929 type Work @default.
• W2613339929 sameAs 2613339929 @default.
• W2613339929 citedByCount "15" @default.
• W2613339929 countsByYear W26133399292018 @default.
• W2613339929 countsByYear W26133399292019 @default.
• W2613339929 countsByYear W26133399292020 @default.
• W2613339929 countsByYear W26133399292021 @default.
• W2613339929 countsByYear W26133399292022 @default.
• W2613339929 countsByYear W26133399292023 @default.
• W2613339929 crossrefType "journal-article" @default.
• W2613339929 hasAuthorship W2613339929A5039057642 @default.
• W2613339929 hasAuthorship W2613339929A5047427155 @default.
• W2613339929 hasAuthorship W2613339929A5055163444 @default.
• W2613339929 hasAuthorship W2613339929A5067595638 @default.
• W2613339929 hasAuthorship W2613339929A5085521139 @default.
• W2613339929 hasAuthorship W2613339929A5089940133 @default.
• W2613339929 hasBestOaLocation W26133399291 @default.
• W2613339929 hasConcept C126322002 @default.
• W2613339929 hasConcept C141071460 @default.
• W2613339929 hasConcept C142724271 @default.
• W2613339929 hasConcept C1862650 @default.
• W2613339929 hasConcept C204787440 @default.
• W2613339929 hasConcept C27081682 @default.
• W2613339929 hasConcept C2776112149 @default.
• W2613339929 hasConcept C2780007613 @default.
• W2613339929 hasConcept C2780076729 @default.
• W2613339929 hasConcept C2780931953 @default.
• W2613339929 hasConcept C535046627 @default.
• W2613339929 hasConcept C67761136 @default.
• W2613339929 hasConcept C71924100 @default.
• W2613339929 hasConceptScore W2613339929C126322002 @default.
• W2613339929 hasConceptScore W2613339929C141071460 @default.
• W2613339929 hasConceptScore W2613339929C142724271 @default.
• W2613339929 hasConceptScore W2613339929C1862650 @default.
• W2613339929 hasConceptScore W2613339929C204787440 @default.
• W2613339929 hasConceptScore W2613339929C27081682 @default.
• W2613339929 hasConceptScore W2613339929C2776112149 @default.
• W2613339929 hasConceptScore W2613339929C2780007613 @default.
• W2613339929 hasConceptScore W2613339929C2780076729 @default.
• W2613339929 hasConceptScore W2613339929C2780931953 @default.
• W2613339929 hasConceptScore W2613339929C535046627 @default.
• W2613339929 hasConceptScore W2613339929C67761136 @default.
• W2613339929 hasConceptScore W2613339929C71924100 @default.
• W2613339929 hasFunder F4320317544 @default.
• W2613339929 hasFunder F4320332161 @default.
• W2613339929 hasFunder F4320337351 @default.
• W2613339929 hasIssue "8" @default.
• W2613339929 hasLocation W26133399291 @default.
• W2613339929 hasLocation W26133399292 @default.
• W2613339929 hasLocation W26133399293 @default.
• W2613339929 hasOpenAccess W2613339929 @default.
• W2613339929 hasPrimaryLocation W26133399291 @default.
• W2613339929 hasRelatedWork W1753898346 @default.
• W2613339929 hasRelatedWork W2079327299 @default.
• W2613339929 hasRelatedWork W2609535710 @default.
• W2613339929 hasRelatedWork W2613339929 @default.
• W2613339929 hasRelatedWork W3096754182 @default.
• W2613339929 hasRelatedWork W4280545603 @default.
• W2613339929 hasRelatedWork W4283323315 @default.
• W2613339929 hasRelatedWork W4321996843 @default.
• W2613339929 hasRelatedWork W4377292146 @default.
• W2613339929 hasRelatedWork W4386102558 @default.

• next